ERBB2 and breast carcinoma: There is well-recognised evidence that supports the use of neoadjuvant chemotherapy (NACT) in clinically high-risk human epidermal growth factor receptor 2 positive (HER2+) breast cancer and triple negative breast cancer (TNBC) [2].